AZD4625 is a potent and selective inhibitor of KRAS G12C

Overview of attention for article published in Molecular Cancer Therapeutics, August 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Average Attention Score compared to outputs of the same age and source

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 16,900 followers.

RRIDs were included in the Molecular Cancer Therapeutics paper "AZD4625 is a Potent and Selective Inhibitor of KRA…" (https://t.co/juMJj6hdTo). Thank you for making your #methodsmatter. #accelerateopenscience

Small Molecule Therapeutics: AZD4625 is a Potent and Selective Inhibitor of KRASG12C. https://t.co/loQGnNj54t https://t.co/6xOVeJyfW6

RT @BertrandBio: $AZN out with preclinical data of their #KRAS #G12C inh., notably in combo w/ SHP2i & aPD-(L)1 AZD4625 is a potent and se…

RT @BertrandBio: $AZN out with preclinical data of their #KRAS #G12C inh., notably in combo w/ SHP2i & aPD-(L)1 AZD4625 is a potent and se…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.